Book a demo
Research & KnowledgeEvent: September 1, 2026

Granite Bio resolved IBD risk mapping using cell-type analyses.

Published

Signal category

Research & Knowledge

Quote

Cell-type resolved IBD risk mapping

Dominik Hartl, MD|Granite Bio team

Company

Industry
Biotechnology Research
Location
Basel, CH
Company size
27 employees

Targeting fundamentals of inflammation, autoimmunity and fibrosis

Founded 2021

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.

Granite Bio resolved IBD risk mapping using cell-type analyses. | SeedOps